GlassScriptPhysician profile
Yevgeniy Sheyn
NPI 1346228152
$3,191.82
in general payments reported to CMS, 2019-2025
26 companies · $995 in 2025
The $995 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $493 · 2020: $51.76 · 2021: $12.01 · 2022: $235 · 2023: $452 · 2024: $952 · 2025: $995.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,399.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $605.72 | 2019-2025 | Krystexxa, Tavneos, Otezla |
| Abbvie INC. | $524.28 | 2023-2025 | Rinvoq, Humira, Qulipta |
| Janssen Biotech, INC. | $383.29 | 2019-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $299.70 | 2019-2025 | |
| Ucb, INC. | $236.88 | 2022-2025 | Cimzia, Bimzelx |
| Fresenius Kabi USA, LLC | $145.30 | 2023-2025 | Idacio |
| Pfizer INC. | $134.99 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $104.55 | 2019-2025 | Orencia |
| Ani Pharmaceuticals, INC. | $98.98 | 2025 | Purified Cortrophin Gel |
| Glaxosmithkline, LLC. | $91.22 | 2019-2025 | Benlysta |
| Mallinckrodt Hospital Products INC. | $84.33 | 2025 | Acthar |
| Aurinia Pharma U.S., INC. | $75.05 | 2022-2024 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $55.83 | 2024 | Strensiq, Ultomiris |
| Astrazeneca Pharmaceuticals LP | $47.27 | 2023-2025 | Saphnelo, Flumist Quadrivalent |
| Genentech USA, INC. | $45.75 | 2019-2023 | Actemra |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $40.77 | 2024-2025 | |
| Horizon Therapeutics Plc | $32.92 | 2019-2022 | |
| Sandoz INC. | $30.16 | 2025 | Hyrimoz |
| Sanofi Pasteur INC. | $29.79 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $24.59 | 2025 | Iovera, Zilretta |
| Saluda Medical Americas, INC. | $23.75 | 2025 | Evoke |
| Celgene Corporation | $20.66 | 2019 | |
| Lilly USA, LLC | $15.49 | 2019 | |
| Hikma Pharmaceuticals USA | $15.41 | 2019 | |
| Merck Sharp & Dohme LLC | $13.44 | 2019 | |
| Depuy Synthes Sales INC. | $11.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yevgeniy Sheyn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.